The oral form of semaglutide, a GLP-1 receptor agonist, has shown no benefit in slowing the progression of cognitive impairment in individuals with Alzheimer’s disease, according to the results of two Phase 3 clinical trials, Evoke and Evoke+. The findings, published in The Lancet, represent a setback for researchers investigating potential new treatments for the devastating neurodegenerative condition. Novo Nordisk, the manufacturer of semaglutide, had already announced the discontinuation of both trials in November 2025, but the detailed results were recently released, confirming the earlier decision.
The trials, Evoke and Evoke+, were initiated based on promising preclinical data. Studies in mice suggested that GLP-1 agonists could positively influence inflammatory, vascular, and metabolic processes believed to play a role in the development of Alzheimer’s disease. This sparked interest in whether the drug, already approved for type 2 diabetes and obesity, could offer a new avenue for treating or preventing cognitive decline. The initial rationale centered on the potential to address metabolic dysfunction in the brain, a growing area of research in Alzheimer’s.
Study Details and Key Findings
The Evoke and Evoke+ trials involved a total of over 1,600 participants with early Alzheimer’s disease or mild cognitive impairment. Participants were randomly assigned to receive either oral semaglutide or a placebo daily for 52 weeks. The primary outcome measure was the change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, a commonly used assessment tool to track the progression of dementia symptoms. Novo Nordisk’s statement confirmed that neither trial demonstrated a statistically significant difference between the semaglutide and placebo groups in terms of CDR-SB change.
Researchers similarly assessed secondary endpoints, including measures of cognitive function, daily living activities, and biomarkers of Alzheimer’s pathology. Again, the results showed no significant benefit with semaglutide compared to placebo. While some exploratory analyses suggested potential signals in certain subgroups, these were not considered robust enough to warrant further investigation. The lack of efficacy was consistent across both trials, bolstering the conclusion that oral semaglutide, at the doses tested, does not halt or slow the progression of cognitive decline in Alzheimer’s disease.
Why the Disappointment? Exploring Potential Reasons
The negative results are particularly noteworthy given the excitement surrounding semaglutide’s potential. Several factors may explain why the drug did not translate into clinical benefit in these trials. One possibility is that the oral formulation of semaglutide may not achieve the same brain concentrations as the injectable version, which is currently used for diabetes and weight management. The bioavailability of oral semaglutide is significantly lower than that of the injectable form, meaning less of the drug reaches the bloodstream and, potentially, the brain.
Another consideration is the timing of intervention. The participants in the Evoke and Evoke+ trials already had detectable cognitive impairment. It’s possible that semaglutide might be more effective if administered earlier in the disease process, before significant neuronal damage has occurred. The “amyloid hypothesis” of Alzheimer’s disease, which posits that the buildup of amyloid plaques in the brain is a primary driver of the disease, is increasingly being challenged by research highlighting the role of metabolic dysfunction and inflammation. Semaglutide’s effects on these pathways may be more relevant in preventing the onset of Alzheimer’s rather than reversing established cognitive decline.
Implications for Alzheimer’s Research and Future Directions
Despite the disappointing outcome, the Evoke and Evoke+ trials provide valuable insights into the complex pathophysiology of Alzheimer’s disease. The findings underscore the challenges of developing effective treatments for this condition and highlight the need for continued research into novel therapeutic targets. The focus is shifting towards a more holistic approach, addressing multiple factors that contribute to the disease, including inflammation, vascular health, and metabolic dysfunction.
Researchers are now exploring other GLP-1 agonists, as well as other drugs that target similar pathways, in clinical trials. The injectable form of semaglutide is also being investigated in separate studies for its potential to modify the course of Alzheimer’s disease. Ongoing research is focused on identifying biomarkers that can predict which individuals are most likely to benefit from specific treatments, paving the way for more personalized approaches to Alzheimer’s care. The search for effective treatments for Alzheimer’s disease remains a critical public health priority, given the growing prevalence of the condition and its devastating impact on individuals, families, and healthcare systems.
The Alzheimer’s Association provides comprehensive information and resources for individuals and families affected by the disease. You can find more information at their website.
Looking ahead, Novo Nordisk plans to continue analyzing the data from the Evoke and Evoke+ trials to gain a deeper understanding of the drug’s effects on Alzheimer’s disease. The company will also focus on developing and evaluating other potential therapies for neurodegenerative disorders. The next major update from Novo Nordisk regarding their Alzheimer’s research is expected in the first quarter of 2027, when they will present a comprehensive analysis of the trial data at a major scientific conference.
This research underscores the complexities of Alzheimer’s disease and the need for continued investigation. Share your thoughts and experiences in the comments below, and please share this article with anyone who may find it informative.
